HighTower Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.15M Sell
17,841
-4,548
-20% -$321K ﹤0.01% 2088
2025
Q4
$1.51M Sell
22,389
-3,749
-14% -$252K ﹤0.01% 1840
2025
Q3
$1.92M Buy
26,138
+8,007
+44% +$532K ﹤0.01% 1659
2025
Q2
$943K Sell
18,131
-6,263
-26% -$356K ﹤0.01% 2051
2025
Q1
$1.56M Buy
24,394
+7,800
+47% +$453K ﹤0.01% 1662
2024
Q4
$793K Sell
16,594
-19,580
-54% -$1M ﹤0.01% 2134
2024
Q3
$2.08M Buy
36,174
+6,075
+20% +$348K ﹤0.01% 1503
2024
Q2
$1.58M Buy
30,099
+5,000
+20% +$219K ﹤0.01% 1577
2024
Q1
$1.01M Sell
25,099
-8,522
-25% -$319K ﹤0.01% 1796
2023
Q4
$1.24M Buy
33,621
+14,633
+77% +$551K ﹤0.01% 1732
2023
Q3
$725K Buy
18,988
+583
+3% +$23.9K ﹤0.01% 1976
2023
Q2
$668K Buy
18,405
+563
+3% +$19.2K ﹤0.01% 2008
2023
Q1
$680K Sell
17,842
-72,510
-80% -$3.4M ﹤0.01% 1905
2022
Q4
$5.14M Sell
90,352
-5,953
-6% -$305K 0.01% 841
2022
Q3
$3.82M Buy
96,305
+80,941
+527% +$3.58M 0.01% 915
2022
Q2
$674K Buy
15,364
+3,412
+29% +$148K ﹤0.01% 1873
2022
Q1
$477K Buy
11,952
+812
+7% +$28.9K ﹤0.01% 2204
2021
Q4
$446K Buy
11,140
+1,505
+16% +$56.2K ﹤0.01% 2232
2021
Q3
$391K Sell
9,635
-519
-5% -$21.7K ﹤0.01% 2231
2021
Q2
$461K Buy
10,154
+896
+10% +$39.7K ﹤0.01% 2096
2021
Q1
$387K Buy
9,258
+2,710
+41% +$124K ﹤0.01% 2135
2020
Q4
$281K Buy
+6,548
New +$235K ﹤0.01% 1983
2019
Q4
Sell
-28,629
Closed -$443K 2451
2019
Q3
$443K Sell
28,629
-500
-2% -$8.24K ﹤0.01% 1580
2019
Q2
$500K Sell
29,129
-500
-2% -$8.07K ﹤0.01% 1513
2019
Q1
$476K Buy
29,629
+1,014
+4% +$16.4K ﹤0.01% 1481
2018
Q4
$418K Buy
28,615
+1,559
+6% +$24.9K ﹤0.01% 1448
2018
Q3
$492K Buy
27,056
+5,707
+27% +$100K ﹤0.01% 1467
2018
Q2
$359K Sell
21,349
-5,519
-21% -$104K ﹤0.01% 1602
2018
Q1
$527K Buy
26,868
+9,320
+53% +$180K ﹤0.01% 1392
2017
Q4
$356K Sell
17,548
-5,882
-25% -$108K ﹤0.01% 1615
2017
Q3
$407K Sell
23,430
-11,419
-33% -$155K ﹤0.01% 1537
2017
Q2
$446K Buy
34,849
+7,499
+27% +$100K ﹤0.01% 1427
2017
Q1
$354K Sell
27,350
-12,200
-31% -$154K ﹤0.01% 1474
2016
Q4
$392K Buy
39,550
+500
+1% +$5.48K ﹤0.01% 1356
2016
Q3
$473K Hold
39,050
0.01% 1267
2016
Q2
$336K Buy
39,050
+5,414
+16% +$53.4K ﹤0.01% 1280
2016
Q1
$319K Buy
33,636
+6,400
+23% +$60.2K ﹤0.01% 1583
2015
Q4
$470K Sell
27,236
-277
-1% -$4.42K 0.01% 1347
2015
Q3
$369K Buy
27,513
+9,625
+54% +$193K ﹤0.01% 1353
2015
Q2
$404K Sell
17,888
-11,787
-40% -$207K 0.01% 1089
2015
Q1
$424K Sell
29,675
-8,100
-21% -$117K 0.01% 1121
2014
Q4
$365K Buy
37,775
+8,500
+29% +$75.5K 0.01% 1153
2014
Q3
$266K Hold
29,275
﹤0.01% 1257
2014
Q2
$289K Hold
29,275
0.01% 1268
2014
Q1
$372K Sell
29,275
-1,000
-3% -$14.8K 0.01% 1093
2013
Q4
$454K Buy
30,275
+500
+2% +$6.43K 0.01% 1002
2013
Q3
$329K Sell
29,775
-2,000
-6% -$16.7K 0.01% 997
2013
Q2
$253K Buy
+31,775
New +$202K 0.01% 1050

Other funds holding HALO

HighTower Advisors's HALO Position: Q1 2026 in Review

HighTower Advisors reduced its Halozyme (HALO) stake by 20% in Q1 2026, selling an estimated $321K and leaving 17,841 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

HighTower Advisors first reported a position in HALO in Q2 2013 and has held it in 48 quarters since. The position peaked at $5.14M in Q4 2022. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • HighTower Advisors held 17,841 shares of Halozyme worth $1.15M as of Q1 2026.
  • HighTower Advisors sold 4,548 Halozyme shares in Q1 2026, an estimated $321K.
  • Halozyme made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2088 holding.
  • HighTower Advisors first reported a position in Halozyme in Q2 2013 and has held it in 48 quarters since.
  • HighTower Advisors's Halozyme position peaked at $5.14M in Q4 2022.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.